Publisher's Synopsis
Semaglutide is a relatively new drug that has quickly become well-known for its effectiveness and special qualities in the treatment of diabetes. We will look at the history, mode of action, and various medical applications of semaglutide in this introduction.
About Semaglutide's Past:
Semaglutide is a member of the group of drugs known as glucagon-like peptide-1 receptor agonists, or GLP-1 RAs, which replicate the effects of the endogenous GLP-1 hormone. Semaglutide was created by the Danish pharmaceutical company Novo Nordisk to improve the treatment of type 2 diabetes mellitus (T2DM). It was created to mitigate some of the drawbacks of previous GLP-1 RAs and enhance glycemic control.
Semaglutide's journey started with intensive research and development to improve its stability, duration of action, and efficacy. It was approved for clinical use after undergoing
extensive clinical trials to assess its safety and efficacy profile.
Action Mechanism:
Semaglutide mainly works by activating the pancreatic GLP-1 receptors, which raises the amount of insulin secreted in response to high blood glucose. Furthermore, it inhibits the release of glucagon, which lowers the amount of glucose produced by the liver. In diabetics, these activities help to lower HbA1c levels and enhance glucose regulation.
Semaglutide's long-acting formulation, which enables once-weekly administration, is one of its unique qualities. Its structural alterations, which increase its stability and resistance to enzyme degradation, are responsible for its extended duration of action.
